CorMedix Inc.  

(Public, NYSEMKT:CRMD)   Watch this stock  
Find more results for CRMD
2.80
+0.07 (2.56%)
After Hours: 2.80 0.00 (0.00%)
May 24, 4:28PM EDT  
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.64 - 2.83
52 week 1.15 - 7.38
Open 2.75
Vol / Avg. 284,632.00/338,845.00
Mkt cap 97.14M
P/E     -
Div/yield     -
EPS -0.49
Shares 36.22M
Beta 0.55
Inst. own 22%
May 6, 2016
Q1 2016 CorMedix Inc Earnings Release (Estimated)
Mar 16, 2016
CorMedix Inc at ROTH Conference
Mar 16, 2016
Q4 2015 CorMedix Inc Earnings Release
Mar 16, 2016
Q4 2015 CorMedix Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -10212.82% -8655.37%
Operating margin -10285.61% -7925.56%
EBITD margin - -7918.38%
Return on average assets -48.00% -86.20%
Return on average equity -52.60% -96.80%
Employees 9 -
CDP Score - -

Address

1430 US Highway 206 Ste 200
BEDMINSTER, NJ 07921-4602
United States - Map
+1-908-5179500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Officers and directors

Cora M. Tellez Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Randy Milby Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
James Altland Interim Chief Financial Officer
Bio & Compensation  - Reuters
Antony E. Pfaffle M.D. Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Myron M. Kaplan Director
Age: 69
Bio & Compensation  - Reuters
Janet M. Dillione Independent Director
Age: 55
Bio & Compensation  - Reuters
Matthew P. Duffy Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael W. George Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven W. Lefkowitz Independent Director
Age: 59
Bio & Compensation  - Reuters